Indacaterol-glycopyrronium combination: all 26 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• QVA Mechanistic Efficacy Study (Receptor Effects, Etc)CompletedNCT02634983Phase 4Results posted
• Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDCompletedNCT02603393Phase 4Results posted
• A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD PatientsCompletedNCT02566031Phase 4Results posted
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT02487498Phase 3Results posted
• Efficacy and Safety Study of QVA149 in COPD PatientsCompletedNCT02487446Phase 3Results posted
• Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD PatientsCompletedNCT02442206Phase 4Results posted
• A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02233543Phase 4Results posted
• Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD PatientsCompletedNCT02125734Phase 4Results posted
• Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.CompletedNCT01996319Phase 3Results posted
• QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)CompletedNCT01782326Phase 3Results posted
• A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.CompletedNCT01727141Phase 3Results posted
• A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow LimitationCompletedNCT01712516Phase 3Results posted
• A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149CompletedNCT01709903Phase 3Results posted
• A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow LimitationCompletedNCT01682863Phase 3Results posted
• Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow LimitationCompletedNCT01610037Phase 3Results posted
• The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01574651Phase 3Results posted
• Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01529632Phase 3Results posted
• The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01490125Phase 3Results posted
• QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01315249Phase 3Results posted
• Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01294787Phase 3Results posted
• Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01285492Phase 3Results posted
• A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01202188Phase 3Results posted
• A Study to Assess the Long-term Safety of QVA149CompletedNCT01120717Phase 3Results posted
• Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsCompletedNCT01120691Phase 3Results posted
• A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDWithdrawnNCT01860066Phase 3
• A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPDWithdrawnNCT01834885Phase 3

← Indacaterol-glycopyrronium combination overview